Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Coherus Oncology (CHRS) over the last 8 years, with Q3 2025 value amounting to -$2.5 million.

  • Coherus Oncology's Change in Inventory fell 13572.46% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 3980.75%. This contributed to the annual value of $32.0 million for FY2024, which is 3163.01% down from last year.
  • As of Q3 2025, Coherus Oncology's Change in Inventory stood at -$2.5 million, which was down 13572.46% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Change in Inventory registered a high of $23.4 million during Q3 2022, and its lowest value of -$7.5 million during Q2 2021.
  • Over the past 5 years, Coherus Oncology's median Change in Inventory value was $9.2 million (recorded in 2021), while the average stood at $7.8 million.
  • As far as peak fluctuations go, Coherus Oncology's Change in Inventory plummeted by 24108.37% in 2021, and later surged by 44362.86% in 2022.
  • Coherus Oncology's Change in Inventory (Quarter) stood at $9.2 million in 2021, then increased by 6.56% to $9.8 million in 2022, then increased by 20.44% to $11.8 million in 2023, then plummeted by 45.28% to $6.5 million in 2024, then plummeted by 138.43% to -$2.5 million in 2025.
  • Its Change in Inventory stands at -$2.5 million for Q3 2025, versus -$3.8 million for Q2 2025 and $22.2 million for Q1 2025.